A2 Biotherapeutics, a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the closing of its $80 million Series C financing round, supported by a syndicate of investors that includes The Column Group and Samsara BioCapital. Proceeds will fund the company's three clinical development programs and advancement of its pipeline of CAR-T cell therapies based on its proprietary Tmod™ platform technology.

A2 Biotherapeutics (A2 Bio) is a clinical-stage biotech company developing first-in-class logic-gated cell therapies to address the high unmet need in cancers. A2 Bio invented the proprietary Tmod™ cell therapy platform to tackle the fundamental challenge in cancer treatment-the ability of cancer medicines to distinguish between tumor and normal cells.